Grantham Mayo Van Otterloo & Co. LLC Increases Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Grantham Mayo Van Otterloo & Co. LLC boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 735.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 25,115 shares of the specialty pharmaceutical company’s stock after buying an additional 22,108 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Jazz Pharmaceuticals were worth $3,093,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth about $25,000. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $28,000. Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $29,000. Jones Financial Companies Lllp lifted its holdings in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares during the period. Finally, UMB Bank n.a. lifted its holdings in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares during the period. Institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Barclays restated an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $145.00 to $179.00 in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Stock Down 2.8 %

JAZZ stock opened at $106.93 on Tuesday. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The firm has a market capitalization of $6.49 billion, a PE ratio of 15.06, a PEG ratio of 1.04 and a beta of 0.42. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a 50-day simple moving average of $131.92 and a two-hundred day simple moving average of $123.06.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the transaction, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at $1,189,587.54. This trade represents a 36.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,736 shares of company stock valued at $4,023,305. Corporate insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.